Onconetix (DE:J4T)
FRANKFURT:J4T
J4T Stock Chart & Stats
€2.82
--
Market closed
€2.82
--
Day’s Range― - ―
52-Week Range€2.80 - €2.82
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€3.48M
Enterprise Value-€3.03M
Total Cash (Recent Filing)€3.72M
Total Debt (Recent Filing)€289.92K
Price to Earnings (P/E)―
Beta-0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding3,691,492
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)16.24
Price to Sales (P/S)313.95
P/FCF Ratio-26.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-172,758.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth PotentialLicensing proprietary technologies to other firms offers a scalable revenue stream, potentially increasing market penetration and financial stability over time.
Strategic PartnershipsCollaborations with larger firms can enhance product development and market reach, providing shared revenue opportunities and access to broader resources.
Innovative Product PortfolioOnconetix's focus on advanced cancer diagnostics and personalized therapeutics positions it well in the biotech industry, leveraging technology for improved patient outcomes.
Bears Say
High Operating LossesSignificant operating losses reflect inefficiencies and financial strain, challenging the company's ability to achieve profitability and necessitating cost management.
Strained Cash FlowsNegative operating cash flow suggests difficulties in covering operational expenses, which can hinder growth initiatives and necessitate external financing.
Negative Profit MarginsPersistent negative profit margins indicate ongoing financial challenges, potentially limiting reinvestment capabilities and affecting long-term viability.
Onconetix News
J4T FAQ
What was Onconetix’s price range in the past 12 months?
Onconetix lowest stock price was €2.80 and its highest was €2.82 in the past 12 months.
What is Onconetix’s market cap?
Onconetix’s market cap is €3.48M.
When is Onconetix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Onconetix’s earnings last quarter?
Currently, no data Available
Is Onconetix overvalued?
According to Wall Street analysts Onconetix’s price is currently Overvalued.
Does Onconetix pay dividends?
Onconetix does not currently pay dividends.
What is Onconetix’s EPS estimate?
Onconetix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Onconetix have?
Onconetix has 3,691,492 shares outstanding.
What happened to Onconetix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Onconetix?
Currently, no hedge funds are holding shares in DE:J4T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Onconetix
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Options Prices
Currently, No data available
---